BAK1 and plasma cell myeloma: Although the mechanism of action of ABT-737 has not been described in detail, it is known that ABT-737 inhibits the protective effect of Bcl-2 and Bcl-xL, an effect that is dependent on Bax or Bak, and activates the cleavage of caspases 8/9 in multiple myeloma cells [105].